Glaxo to pay $750 million for sale of bad products
GlaxoSmithKline, the British drug giant, has agreed to pay $750 million to settle criminal and civil complaints that the company for years knowingly sold contaminated baby ointment and an ineffective antidepressant — the latest in a growing number of whistle-blower lawsuits that drug makers have settled with multimillion-dollar fines.
Altogether, GlaxoSmithKline sold 20 drugs with questionable safety that were made at a huge plant in Puerto Rico that for years was rife with contamination.
- Surgical Checklists Unused in 10% of Hospitals, CMS Data Shows
- Doctors Feel Pressure to Accept Risk-based Reimbursement
- 3 Insider Tips on Cutting Costs without Strangling Growth
- 4 Tectonic Shifts Shaking Up Healthcare
- As Medicare Advantage Cuts Loom, Disagreement Over Program's Stability
- A Fresh Look at End-of-Life Care
- Roundtable: To Arrest HAIs, Culture Trumps Campaigns
- Heart Attack Patient Costs Skyrocket Beyond 30 Days
- 3 in 4 Patients Want E-mail Consultations
- ACGME Chief Sees 'Huge' Risk of Error in Proposed Assistant Physician Licensure